Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of Steatohepatitis

Hepatocellular carcinoma (HCC) is the strongest independent predictor of mortality in non-alcoholic steatohepatitis (NASH)-related cirrhosis. The effects and mechanisms of combination of sodium-dependent glucose cotransporter inhibitor and canagliflozin (CA) and dipeptidyl peptidase-4 inhibitor and...

Descripción completa

Detalles Bibliográficos
Autores principales: Ozutsumi, Takahiro, Namisaki, Tadashi, Shimozato, Naotaka, Kaji, Kosuke, Tsuji, Yuki, Kaya, Daisuke, Fujinaga, Yukihisa, Furukawa, Masanori, Nakanishi, Keisuke, Sato, Shinya, Sawada, Yasuhiko, Saikawa, Soichiro, Kitagawa, Koh, Takaya, Hiroaki, Kawaratani, Hideto, Kitade, Mitsuteru, Moriya, Kei, Noguchi, Ryuichi, Akahane, Takemi, Mitoro, Akira, Yoshiji, Hitoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139722/
https://www.ncbi.nlm.nih.gov/pubmed/32245205
http://dx.doi.org/10.3390/ijms21062164

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139722/
https://www.ncbi.nlm.nih.gov/pubmed/32245205
http://dx.doi.org/10.3390/ijms21062164

Ejemplares similares